217.75USD+7.43%Mkt Cap: —P/E: 47.581d ago
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and arr…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value33.87B $
Revenue (TTM)4.49B $
Gross Profit3.05B $
Net Income (TTM)824.00M $
Revenue/Share29.57 USD
Last Price217.75 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees8.6K
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)47.58
P/E (Forward)—
PEG—
EV/EBITDA29.32
EV/Revenue7.54
P/S—
P/B11.40
EPS (TTM)4.55
EPS (Forward)—
52W Range
185.0093% of range220.15
52W High220.15 USD
52W Low185.00 USD
Profitability
Gross Margin67.93%
Oper. Margin21.14%
EBITDA Margin25.70%
Profit Margin18.34%
ROE32.34%
ROA8.67%
Growth
Revenue Growth9.40%
Earnings Growth-9.40%
Cash Flow & Leverage
Operating CF1.10B $
CapEx (TTM)—
FCF Margin17.75%
FCF Yield—
Net Debt1.36B $
Net Debt/EBITDA1.18
Balance Sheet
Debt/Equity89.04
Current Ratio1.80
Quick Ratio1.25
Book Value/Sh18.80 USD
Cash/Share7.735 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.147.00M
Float148.48M
Insiders0.21%
Institutions105.90%
Technical
SMA 50138.95 (+56.7%)
SMA 200149.37 (+45.8%)
Beta1.46
S&P 52W Chg18.16%
Avg Vol (30d)1.32K
Avg Vol (10d)9.52K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—